The current financial score of IRadimed Corp is 9.12. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 20.47M, representing a year-over-year increase of 0.28%, while its net profit experienced a year-over-year increase of 9.63%.
The current valuation score of IRadimed Corp is 6.77. Its current P/E ratio is 44.64, which is 41.30% below the recent high of 63.08 and 40.02% above the recent low of 26.78.
The current earnings forecast score of IRadimed Corp is 8.00. The average price target is 118.00, with a high of 120.00 and a low of 116.00.
The current price momentum score of IRadimed Corp is 2.77. Currently, the stock price is trading between the resistance level at 87.44 and the support level at 79.72, making it suitable for range-bound swing trading.
The current institutional shareholding score of IRadimed Corp is 5.00. The latest institutional shareholding proportion is 65.08%, representing a quarter-over-quarter increase of 13.11%. The largest institutional shareholder is James Simons, holding a total of 394.41K shares, representing 0.05% of shares outstanding, with 30.24% increase in holdings.
The current risk assessment score of IRadimed Corp is 8.39. The company's beta value is 0.91. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.